BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 20028747)

  • 1. The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis.
    Memmott RM; Dennis PA
    Clin Cancer Res; 2010 Jan; 16(1):4-10. PubMed ID: 20028747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin prevents tobacco carcinogen--induced lung tumorigenesis.
    Memmott RM; Mercado JR; Maier CR; Kawabata S; Fox SD; Dennis PA
    Cancer Prev Res (Phila); 2010 Sep; 3(9):1066-76. PubMed ID: 20810672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors.
    Granville CA; Warfel N; Tsurutani J; Hollander MC; Robertson M; Fox SD; Veenstra TD; Issaq HJ; Linnoila RI; Dennis PA
    Clin Cancer Res; 2007 Apr; 13(7):2281-9. PubMed ID: 17404113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
    Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Targeting of the AKT-mTOR pathway in head and neck and lung cancer].
    Vignot S; Haberer S; Besse B
    Bull Cancer; 2009; 96 Suppl 1():S57-63. PubMed ID: 19433374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
    Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
    Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy.
    Papadimitrakopoulou V; Adjei AA
    J Thorac Oncol; 2006 Sep; 1(7):749-51. PubMed ID: 17409953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
    Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun SY
    Cancer Res; 2008 Sep; 68(18):7409-18. PubMed ID: 18794129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor-α induced protein 8 (TNFAIP8/TIPE) family is differentially expressed in oral cancer and regulates tumorigenesis through Akt/mTOR/STAT3 signaling cascade.
    Padmavathi G; Monisha J; Bordoloi D; Banik K; Roy NK; Girisa S; Singh AK; Longkumer I; Baruah MN; Kunnumakkara AB
    Life Sci; 2021 Dec; 287():120118. PubMed ID: 34740574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [mTOR inhibitors].
    Oya M
    Nihon Rinsho; 2010 Jun; 68(6):1067-71. PubMed ID: 20535957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck.
    Liu FY; Zhao ZJ; Li P; Ding X; Zong ZH; Sun CF
    Br J Oral Maxillofac Surg; 2010 Jun; 48(4):291-6. PubMed ID: 19615795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [mTOR and non-small cell lung cancer].
    Wang L; Xu S; Yue W
    Zhongguo Fei Ai Za Zhi; 2010 Jan; 13(1):69-72. PubMed ID: 20672708
    [No Abstract]   [Full Text] [Related]  

  • 17. The potential role of mTOR inhibitors in the treatment of endocrine tumors.
    Grozinsky-Glasberg S; Shimon I
    J Endocrinol Invest; 2010 Apr; 33(4):276-81. PubMed ID: 20503485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of TIPE3 reduced the proliferation, survival and migration of lung cancer cells through inactivation of Akt/mTOR, NF-κB, and STAT-3 signaling cascades.
    Bordoloi D; Harsha C; Padmavathi G; Banik K; Sailo BL; Roy NK; Girisa S; Thakur KK; Khwairakpam AD; Chinnathambi A; Alahmadi TA; Alharbi SA; Shakibaei M; Kunnumakkara AB
    Life Sci; 2022 Mar; 293():120332. PubMed ID: 35041835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells.
    Tsurutani J; Castillo SS; Brognard J; Granville CA; Zhang C; Gills JJ; Sayyah J; Dennis PA
    Carcinogenesis; 2005 Jul; 26(7):1182-95. PubMed ID: 15790591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway.
    Liu F; Gao S; Yang Y; Zhao X; Fan Y; Ma W; Yang D; Yang A; Yu Y
    Oncol Rep; 2018 Mar; 39(3):1523-1531. PubMed ID: 29328421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.